Subcutaneous Daratumumab Approved by EC in Smoldering Multiple Myeloma
Cancer Network Staff: The management of immune-checkpoint inhibitor toxicities in melanoma is a constantly evolving aspect in cancer treatment. Deep understanding of these treatments is key to counteract potential side effects and improve patient outcomes.
Fast Tracking High-Grade Glioma Treatment: The FDA has granted fast track designation to SRN-101 for treating recurrent high-grade glioma. This expedited development and review process not only accelerates the introduction of new therapies but also gives more hope to patients.
Saad Z. Usmani, MD, MBA, FACP: A novel small molecule, KTX-1001, has shown early activity in the treatment of pretreated multiple myeloma. These developments could potentially lead to further advancements in cancer therapy methods.
Roman Fabbricatore: Quality of life outcomes with protons and photons in oropharyngeal squamous cell carcinoma (OPSCC) have been examined. A refined understanding can guide the choice of treatment thereby bettering patient quality of life.
Oncology Staff: The use of PSMA-Directed imaging and radioligand therapy in prostate cancer is a critical focus. The understanding of these therapies is paramount to ensure effective treatment decisions.
